Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The National Cancer Institute (NCI) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 12 clinical trials at NIH that match your search criteria

Cancer by type: Kidney (Renal Cell) Cancer

Trial and Protocol Number Kidney (Renal Cell) Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma NCI-08-C-0039	W. Marston Linehan 301-496-6353	David Draper 301-435-5614 draperd@mail.nih.gov
A Phase II Study of the c-Met RTK Inhibitor GSK 1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma (PRC) NCI-07-C-0121	Ramaprasad Srinivasan 301-496-6353	Martha Ninos 301-435-8897 mninos@mail.nih.gov
A Phase II Clinical Trial of BMS-247550 (NSC 710428), an Epothilone B Analog, in Renal Cell Carcinoma NCI-02-C-0130	Antonio Tito Fojo 301-402-1357	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
Phase I/II
Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells NCI-08-C-0088	Daniel Fowler 301-435-8641	Mike Krumlauf 301-594-2056 krumlaum@mail.nih.gov

Trial and Protocol Number Leiomyomatosis	Principal Investigator	Referral Contact
No Phase
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer NCI-03-C-0066	W. Marston Linehan 301-496-6353

Trial and Protocol Number Melanoma, Skin	Principal Investigator	Referral Contact
Phase I
A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma NCI-07-C-0114	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov

Trial and Protocol Number Solid Tumor (Adult)	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-p53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination NCI-08-C-0155	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Guinevere Chun 301-451-7868 gchun@mail.nih.gov

Trial and Protocol Number Von Hippel-Lindau	Principal Investigator	Referral Contact
Phase II
A Phase II Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors NCI-08-C-0020	W. Marston Linehan 301-496-6353	Sarah Fowler 301-435-6255 fowlers@mail.nih.gov
A Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Von Hippel Lindau Disease and Renal Tumors NCI-04-C-0238	W. Marston Linehan 301-496-6353
No Phase
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders NCI-89-C-0086	W. Marston Linehan 301-496-6353

If there are no studies listed for your specific disease type, please search under:

Solid Tumor (advanced malignancy)